6th Circ. Revives Esperion Investor Suit Over Cholesterol Drug
The Sixth Circuit on Thursday revived a securities fraud suit claiming that Esperion Therapeutics Inc. misled a putative class of investors about a new cholesterol drug, finding the company's explanations for...To view the full article, register now.
Already a subscriber? Click here to view full article